OPT-821 adjuvant
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for OPT-821 adjuvant, covering 2016-08-10 to 2016-08-10. Get the full timeline:
Most recent: Clinical Trial Update: Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma [NA]